

Irwin Walker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11656652/publications.pdf>

Version: 2024-02-01

21
papers

1,586
citations

567281

15
h-index

752698

20
g-index

21
all docs

21
docs citations

21
times ranked

1672
citing authors

#	ARTICLE	IF	CITATIONS
1	The Role of the Plasma from Platelet Concentrates in Transfusion Reactions. <i>New England Journal of Medicine</i> , 1994, 331, 625-628.	27.0	504
2	Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. <i>Lancet Oncology</i> , The, 2016, 17, 164-173.	10.7	283
3	A randomized controlled trial comparing plasma removal with white cell reduction to prevent reactions to platelets. <i>Transfusion</i> , 1999, 39, 231-238.	1.6	139
4	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1343-1359.	2.0	105
5	Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells. <i>Blood</i> , 2016, 127, 3082-3091.	1.4	83
6	Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel. <i>Bone Marrow Transplantation</i> , 2020, 55, 1093-1102.	2.4	78
7	Health status and health-related quality of life associated with hemophilia. <i>American Journal of Hematology</i> , 2002, 71, 152-160.	4.1	76
8	Health status and health-related quality of life associated with von Willebrand disease. <i>American Journal of Hematology</i> , 2003, 73, 108-114.	4.1	72
9	Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Haematology</i> . 2020. 7. e100-e111.	4.6	59
10	Liberal Versus Restrictive Red Blood Cell Transfusion Thresholds in Hematopoietic Cell Transplantation: A Randomized, Open Label, Phase III, Noninferiority Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1463-1473.	1.6	32
11	Myositis ossificans in hemophilia. <i>Skeletal Radiology</i> , 1981, 7, 27-31.	2.0	27
12	Filgrastim-Stimulated Bone Marrow Compared with Filgrastim-Mobilized Peripheral Blood in Myeloablative Sibling Allografting for Patients with Hematologic Malignancies: A Randomized Canadian Blood and Marrow Transplant Group Study. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1410-1415.	2.0	22
13	Transfusion of Red Cells in Hematopoietic Stem Cell Transplantation (TRIST Study): A Randomized Controlled Trial Evaluating 2 Red Cell Transfusion Thresholds. <i>Blood</i> , 2016, 128, 1032-1032.	1.4	22
14	CD56 ^{bright} natural killer regulatory cells in filgrastim primed donor blood or marrow products regulate chronic graft- <i>versus</i> -host disease: the Canadian Blood and Marrow Transplant Group randomized 0601 study results. <i>Haematologica</i> , 2017, 102, 1936-1946.	3.5	20
15	Hepatitis C Infection in Patients With Hemophilia: Results of a National Survey. <i>Transfusion Medicine Reviews</i> , 1994, 8, 210-217.	2.0	19
16	Thymoglobulin Decreases the Need for Immunosuppression at 12 Months after Myeloablative and Nonmyeloablative Unrelated Donor Transplantation: CBMTG 0801, a Randomized, Controlled Trial. <i>Blood</i> , 2014, 124, 38-38.	1.4	15
17	The use of anti- ϵ to improve post-transfusion platelet response: a randomized trial. <i>British Journal of Haematology</i> , 1995, 89, 163-168.	2.5	11
18	Higher levels of free plasma mitochondrial DNA are associated with the onset of chronic GvHD. <i>Bone Marrow Transplantation</i> , 2018, 53, 1263-1269.	2.4	10

#	ARTICLE	IF	CITATIONS
19	Anti-Thymocyte Globulin Prophylaxis Induces a Decrease in Naive Th Cells to Inhibit the Onset of Chronic Graft-versus-Host Disease: Results from the Canadian Bone Marrow Transplant Group (CBMTG) 0801 Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 438-444.	2.0	8
20	A Systematic Review and Meta-Analysis of Thalidomide in Patients with Previously Untreated Multiple Myeloma.. <i>Blood</i> , 2006, 108, 3570-3570.	1.4	1
21	Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis â€œ Authors' reply. <i>Lancet Haematology</i> ,the, 2020, 7, e364-e365.	4.6	0